Central nervous system toxicity from cancer treatment

Current Oncology Reports

Volumn 6, Issue 1, 2004, Pages 11-19

  Armstrong, Terri ^a   Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BENZODIAZEPINE; BUSULFAN; CISPLATIN; CORTICOSTEROID; CYTARABINE; DIAZEPAM; FLUOROURACIL; FOSPHENYTOIN SODIUM; GINKGO BILOBA EXTRACT; HALOPERIDOL; IFOSFAMIDE; INTERFERON; LORAZEPAM; METHOTREXATE; METHYLPHENIDATE; METRONIDAZOLE; MIDAZOLAM; MORPHINE; NITROSOUREA; OLANZAPINE; PETHIDINE; PHENOTHIAZINE DERIVATIVE; POTASSIUM ION; PROPOFOL; RISPERIDONE; SODIUM ION; UNINDEXED DRUG; VINCRISTINE SULFATE;

ACIDEMIA; AGGRESSION; ATAXIA; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN CALCIFICATION; BRAIN DISEASE; BRAIN NECROSIS; BRAIN TUMOR; BRAIN VENTRICLE DILATATION; BREATHING DISORDER; CANCER; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS DISORDER; DELIRIUM; DEMENTIA; DISORIENTATION; DRUG MEGADOSE; DRUG TARGETING; DYSMETRIA; EPILEPTIC STATE; GAIT DISORDER; HALLUCINATION; HUMAN; HYPERACTIVITY; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; KIDNEY FAILURE; LEPTOMENINX; LEUKOENCEPHALOPATHY; MEMORY DISORDER; MOTOR DYSFUNCTION; NEUROTOXICITY; NYSTAGMUS; OCCLUSIVE CEREBROVASCULAR DISEASE; ONCOLOGY; PATIENT CARE; PERCEPTION DISORDER; PERSONALITY DISORDER; RESTLESSNESS; REVIEW; SEIZURE; SLEEP WAKING CYCLE; SOMNOLENCE; SPEECH DISORDER; SYMPTOMATOLOGY; THOUGHT DISORDER; WHITE MATTER;

EID: 3142511049     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-996-0004-x     Document Type: Review

References (66)

1. Cohen MZ, Armstrong TS: Cognitive dysfunction. In Cancer Symptom Management, edn 3. Edited by Yarbro CH, Frogge MH, Goodman M. Sudbury, MA: Jones and Bartlett; 2003:635-647.
2. Tuma R, DeAngelis LM: Altered mental status in patients with cancer. Arch Neurol 2000, 57:1727-1731.
3. Breitbart W, Strout D: Delirium in the terminally ill. Clin Geriatr Med 2000, 16:357-372.
4. Casarett DJ, Inouye SK: Diagnosis and management of delirium near the end of life. Ann Intern Med 2001, 135:32-40.
5. Lawlor PG, Gagnon B, Mancini IL, et al.: Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med 2000, 160:786-794.
6. Siegal T: Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep 2003, 5:41-49.
7. Bird, T: Memory loss and dementia. In Harrison's On-Line, New York: McGraw Hill; 2001. http://www.harrisonsonline.com
8. Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995, 4:61-66.
9. Cimprich B, Ronis DL: Attention and symptom distress in women with and without breast cancer. Nurs Res 2001, 50:86-94.
10. Cull A, Stewart M, Altman DG: Assessment of and intervention for psychosocial problems in routine oncology practice. Br J Cancer 1995, 72:229-235.
11. Vigliani MC, Duyckaerts C, Hauw JJ, et al.: Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neurooncol 1999, 41:137-149.
12. Keime-Guibert F, Napolitano M, Delattre JV: Neurological complications of radiotherapy and chemotherapy. J Neurol 1998, 245:695-708.
13. Faithful S: Patients' experience following cranial radiotherapy: a study of the somnolence syndrome. J Adv Nursing 1991, 16:939-946.
14. Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493.
15. Archibald YM, Lunn D, Ruttan LA, et al.: Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994, 80:247-253.
16. Armstrong C, Mollman J, Corn BW, et al.: Effects of radiation therapy on adult brain behavior: evidence for a rebound phenomenon in a phase I trial. Neurology 1993, 43:1961-1965.
17. Lilja AM, Portin RI, Hamalainan PI, Salminen EK: Short-term effects of radiotherapy on attention and memory performances in patients with brain tumors. Cancer 2001, 91:2361-2368.
18. Kiebert GM, Curran D, Aaronson NK, et al.: Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase II trial on dose response (EORTC trial 22844). Eur J Cancer 1998, 34:1902-1909.
19. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S: Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990, 26:596-600.
20. Meyers CA, Obbens EA, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991, 68:88-92.
21. Valentine AD, Meyers CA, Kling MA, et al.: Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998, 25:39-47.
22. Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001, 63:376-386.
23. Ch'ien LT, Aur RJ, Verzosa MS, et al.: Progression of methotrexate-induced leukoencephalopathy in children with leukemia. Med Pediatr Oncol 1981, 9:133-141.
24. Price RA: Histopathology of CNS leukemia and complications of therapy. Am J Pediatr Hematol Oncol 1979, 1:21-30.
25. Meadows AT, Evans AE: Effects of chemotherapy on the central nervous system: a study of parenteral methotrexate in longterm survivors of leukemia and lymphoma in childhood. Cancer 1976, 37:1079-1085.
26. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65(Suppl 1):89-98.
27. Inouye SK: Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. Ann Med 2000, 32:257-263.
28. Levine PM, Silberfarb PM, Lipowski ZJ: Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978, 42:1385-1391.
29. Silberfarb P: Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 1983, 34:35-46.
30. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001, 19:812-820.
31. Bender CM, Paraska KK, Sereika SM, et al.: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 2001, 21:407-424.
32. Hahn MB, Jassak PF: Nursing management of patients receiving interferon. Semin Oncol Nurs 1988, 4:95-101.
33. Bender CM: Cognitive dysfunction associated with cancer and cancer therapy. Medsurg Nurs 1995, 4:398-399.
34. Meyers CA, Scheibel RS: Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Huntingt) 1990, 4:115-122.
35. Leskinen S, Lapela M, Lindholm P, Minn H: Metabolic imaging by positron emission tomography in oncology. Ann Med 1997, 29:271-274.
36. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002, 136:42-53.
37. Cimprich B: Attentional fatigue following breast cancer surgery. Res Nurs Health 1992, 15:199-207.
38. Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16: 2522-2527.
39. Thompson S, Leigh L, Christensen R, et al.: Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001, 19:1802-1808.
40. Boyle DM: Confusion/delirium. In Clinical Manual for the Oncology Advanced Practice Nurse. Edited by Hawkins RA. Pittsburgh, PA: Oncology Nursing Press; 2000:721-728.
41. Kuebler KK, Heidrich DE: Delirium/acute confusion. In End of Life Care. Edited by Heidrich DE. Philadelphia: WB Saunders; 2002:253-267.
42. Meagher DJ: Delirium: optimising management. BMJ 2001, 322:144-149.
43. Beaumont A, Whittle IR: The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 2000, 142:1-15.
44. Goldring S, Rich KM, Picker S: Experience with gliomas in patients presenting with a chronic seizure disorder. Clin Neurosurg 1986, 33:15-42.
45. Cairncross JG, Posner JB: Neurologic complications of systemic cancer. In Oncologic Emergencies. Edited by Bornstein RD. New York: Grune and Stratton; 1981:73-96.
46. Szeto HH, Inturrisi CE, Houde R, et al.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977, 86:738-741.
47. Gregory RE, Grossman S, Sheidler VR: Grand mal seizures associated with high-dose intravenous morphine infusions: incidence and possible etiology. Pain 1992, 51:255-258.
48. Armstrong TS, Kanusky J, Gilbert MR: Seize the moment to learn about epilepsy in the person with cancer. Clin J Oncol Nursing 2003, 7:163-169.
49. Collins RC, Al-Mondhiry H, Chernik NL, Posner JB: Neurologic manifestations of intravascular coagulation in patients with cancer: a clinicopathologic analysis of 12 cases. Neurology 1975, 25:795-806.
50. Rosen P, Armstrong D: Nonbacterial thrombotic endocarditis in patients with malignant neoplastic diseases. Am J Med 1973, 54:23-29.
51. Chan KW, Mullen CA, Worth LL, et al.: Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002, 29:963-965.
52. Leppik IE: Contemporary Diagnosis and Management of the Patient with Epilepsy. Newton, PA: Handbooks in Healthcare; 2000.
53. Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249:1452-1454.
54. Dropcho EJ: Paraneoplastic diseases of the nervous system. Curr Treat Options Neurol 1999, 1:417-427.
55. Furneaux HM, Rosenblum MK, Dalmau J, et al.: Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990, 322:1844-1851.
56. Anderson NE, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol 1988, 24:559-567.
57. Riehl JL, Brown WJ: Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964, 14:961-967.
58. Bixenman WW, Nicholls JV, Warwick OH: Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol 1977, 83:789-793.
59. Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG: Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964, 41:15-18.
60. Grossman L, Baker MA, Sutton DM, Deck JH: Central nervous system toxicity of high-dose cytosine arabinoside. Med Pediatr Oncol 1983, 11:246-250.
61. Hwang TL, Yung WK, Estey EH, Fields WS: Central nervous system toxicity with high-dose Ara-C. Neurology 1985, 35:1475-1479.
62. Benger A, Browman GP, Walker IR, Preisler HD: Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a Leukemia Intergroup report. Cancer Treat Rep 1985, 69:240-241.
63. Moore DH, Fowler WC Jr, Crumpler LS: 5-Fluorouracil neurotoxicity. Gynecol Oncol 1990, 36:152-154.
64. Winkelman MD, Hines JD: Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 1983, 14:520-527.
65. Gottlieb D, Bradstock K, Koutts J, et al.: The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987, 60:1439-1441.
66. Damon LE, Mass R, Linker CA: The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 1989, 7: 1563-1568.